Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN1042 |
Synonyms | |
Therapy Description |
GEN1042 is a bispecifc agonistic antibody that binds to CD40 and TNFRSF9 (CD137; 4-1BB), potentially resulting in increased T cell proliferation and anti-tumor immune response (PMID: 30400822). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN1042 | BNT 312|BNT-312|BNT312|GEN-1042|GEN 1042 | CD40 Antibody 14 TNFRSF9 Antibody 32 | GEN1042 is a bispecifc agonistic antibody that binds to CD40 and TNFRSF9 (CD137; 4-1BB), potentially resulting in increased T cell proliferation and anti-tumor immune response (PMID: 30400822). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05491317 | Phase Ib/II | GEN1042 GEN1042 + Pembrolizumab | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Recruiting | FRA | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 4 |